Science Abstracts
Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder
June 2008
June 2008
Authors : Stephen V Faraone
Affliation : Director, Medical Genetics Research, Professor of Psychiatry and Professor of Neuroscience and Physiology Director, SUNY Upstate Medical University, Child and Adolescent Psychiatry Research, 750 East Adams Street, Syracuse, NY 13210, USA ; ; faraones@upstate.edu
DOI : 10.1517/14656566.9.9.1565
Published in : Expert Opin. Pharmacother. Volume 9 Issue 9 2008 pages 1565 1574
Subject: Drug Evaluations
Keywords: abuse , adults , attention deficit/hyperactivity disorder , children , lisdexamfetamine , lisdexamfetamine dimesylate , pharmacokinetics , prodrug
Abstract
Please Login to read the full article.
RELATED CONTENT
NEWS
- US Capitol Capsule: Group proposes efforts to ensure US innovation competitiveness
- Study: No increased cardiovascular risk found with ADHD drugs in adults
- Positive Ph III data may mark start of European push in ADHD for Shire
- US Capitol Capsule: Use of mind-altering medicines in children, elderly under fire
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
